Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Fig. 2

KM estimates of PFS and OS: patients with EGFR Mut + advanced NSCLC by therapy Kaplan-Meier estimates of progression-free survival (a and b) and overall survival (c and d), of patients with EGFR Mut + advanced NSCLC who received either a TKI (a and c) or gefitinib (b and d) prior to first disease progression compared with those patients who did not receive a TKI prior to first disease progression. KM, Kaplan-Meier; Mut+, mutation-positive; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor

Back to article page
\